Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs — Georgia, 2018
Authors:
- Ketevan StviliaKSKetevan Stvilia
- Philip R. SpradlingPSPhilip R. Spradling
- Alexander AsatianiAAAlexander Asatiani
- Maka GogiaMGMaka Gogia
- Khatuna KutateladzeKKKhatuna Kutateladze
- Maia ButsashviliMBMaia Butsashvili
- Jaba ZarkuaJZJaba Zarkua
- Tengiz TsertsvadzeTTTengiz Tsertsvadze
- Lali SharvadzeLSLali Sharvadze
- Maia JaparidzeMJMaia Japaridze
- Tinatin KuchuloriaTKTinatin Kuchuloria
- Lia GvinjiliaLGLia Gvinjilia
- 26 July 2019
- journal article
- research article
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 68 (29) , 637-641
Abstract
Following the launch of the hepatitis C elimination program, the number of hepatitis C virus antibody tests performed at needle and syringe programs has increased fivefold.Keywords
This publication has 3 references indexed in Scilit:
- Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for eliminationBMC Public Health, 2019
- Launch of a Nationwide Hepatitis C Elimination Program — Georgia, April 2015MMWR. Morbidity and Mortality Weekly Report, 2015
- Prevalence of Hepatitis C, HIV, and Risk Behaviors for Blood-Borne Infections: A Population-Based Survey of the Adult Population of T'bilisi, Republic of GeorgiaJournal of Urban Health, 2006